CN111918964B - 促进免疫细胞增殖的方法 - Google Patents

促进免疫细胞增殖的方法 Download PDF

Info

Publication number
CN111918964B
CN111918964B CN201980022452.0A CN201980022452A CN111918964B CN 111918964 B CN111918964 B CN 111918964B CN 201980022452 A CN201980022452 A CN 201980022452A CN 111918964 B CN111918964 B CN 111918964B
Authority
CN
China
Prior art keywords
seq
acid sequence
amino acid
immune cell
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980022452.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111918964A (zh
Inventor
凌有国
郭昊
何晓文
马海立
李慧姣
王华菁
应碧
杨焕凤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oricell Therapeutics Co Ltd
Original Assignee
Oricell Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oricell Therapeutics Co Ltd filed Critical Oricell Therapeutics Co Ltd
Publication of CN111918964A publication Critical patent/CN111918964A/zh
Application granted granted Critical
Publication of CN111918964B publication Critical patent/CN111918964B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980022452.0A 2018-03-26 2019-03-25 促进免疫细胞增殖的方法 Active CN111918964B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018102518757 2018-03-26
CN201810251875 2018-03-26
PCT/CN2019/079576 WO2019184886A1 (zh) 2018-03-26 2019-03-25 促进免疫细胞增殖的方法

Publications (2)

Publication Number Publication Date
CN111918964A CN111918964A (zh) 2020-11-10
CN111918964B true CN111918964B (zh) 2025-05-30

Family

ID=68059463

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980022452.0A Active CN111918964B (zh) 2018-03-26 2019-03-25 促进免疫细胞增殖的方法

Country Status (5)

Country Link
US (1) US12005080B2 (https=)
EP (1) EP3778876A4 (https=)
JP (2) JP2021518149A (https=)
CN (1) CN111918964B (https=)
WO (1) WO2019184886A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022206975A1 (zh) * 2021-04-02 2022-10-06 原启生物科技(上海)有限责任公司 Cldn18.2抗原结合蛋白及其用途
CN117136199A (zh) * 2021-04-27 2023-11-28 原启生物科技(上海)有限责任公司 靶向bcma的嵌合抗原受体及其应用
WO2023030272A1 (zh) * 2021-08-30 2023-03-09 原启生物科技(上海)有限责任公司 抗gprc5d抗原结合蛋白及其用途
JP2025505933A (ja) * 2022-01-06 2025-03-05 オリセル セラピューティクス カンパニー リミテッド Ｍｓｌｎを標的とする抗原結合タンパク質及びその使用
CN116656614A (zh) * 2022-02-17 2023-08-29 杭州乾合细胞生物科技有限公司 一种靶向Her-2的CAR-NK细胞及其应用
CN114891115B (zh) * 2022-02-18 2025-07-18 杭州美中疾病基因研究院有限公司 一种car细胞疗法用核酸构建体及其慢病毒载体、细胞制剂和应用
WO2024251290A1 (en) * 2023-06-09 2024-12-12 Suzhou Cure Genetics Biosciences Co., Limited Engineered immune cells and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108392492A (zh) * 2017-12-28 2018-08-14 中国人民解放军第二军医大学东方肝胆外科医院 Ldlr过表达在nk细胞过继治疗中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3169703T4 (fi) * 2014-07-16 2024-03-01 Hinrich Abken Kimeerinen antigeenireseptori ja sen käyttö
WO2017040287A1 (en) * 2015-08-28 2017-03-09 Serpin Pharma, Llc Methods for treatment of diseases
GB201516972D0 (en) * 2015-09-25 2015-11-11 Epiontis Gmbh LRP5 as epigenetic marker for the identification of immune cells, in particular B-cells
KR20180063320A (ko) * 2015-10-20 2018-06-11 카이트 파마 인코포레이티드 T 세포 요법을 위한 t 세포를 제조하는 방법
WO2018009972A1 (en) * 2016-07-14 2018-01-18 Peter Maccallum Cancer Institute Chimeric antigen receptor modified t cells
EP3600418A4 (en) * 2017-03-24 2021-01-13 Yale University LOW DENSITY LIPOPROTEIN RECEPTOR-BOUND PROTEIN-5 INHIBITION WHICH SUPPRESSES TUMOR FORMATION

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108392492A (zh) * 2017-12-28 2018-08-14 中国人民解放军第二军医大学东方肝胆外科医院 Ldlr过表达在nk细胞过继治疗中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Co-expressing LRP6 With Anti-CD19 CAR-T Cells for Improved Therapeutic Effect Against B-ALL;Ping He等;《Frontiers in Oncology》;20200915;第第10卷卷;第1-9页 *

Also Published As

Publication number Publication date
JP2025023986A (ja) 2025-02-19
JP2021518149A (ja) 2021-08-02
CN111918964A (zh) 2020-11-10
US20210106620A1 (en) 2021-04-15
WO2019184886A1 (zh) 2019-10-03
EP3778876A4 (en) 2022-01-12
US12005080B2 (en) 2024-06-11
EP3778876A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
CN111918964B (zh) 促进免疫细胞增殖的方法
CN110872577B (zh) 修饰的免疫细胞及其应用
AU2017320776B2 (en) Adenovirus armed with bispecific T cell activator
EP3389682B1 (en) Group b adenovirus encoding an anti-tcr-complex antibody or fragment
JP6971986B2 (ja) 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞
He et al. Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer
CN117305250A (zh) 工程化天然杀伤细胞及其用途
CN107523549A (zh) 一种高效稳定表达激活型抗体的car‑t细胞及其用途
CN113677353A (zh) 修饰细胞的扩增及其用途
JPWO2019124468A1 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ−７、及びｃｃｌ１９を発現する免疫担当細胞
CN114786686A (zh) Gold控制的转基因的联合疗法
JP2021511060A (ja) 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現
WO2023025788A1 (en) Il-10 expressing cells for enhanced cancer immunotherapies
CN110225760A (zh) T细胞免疫疗法
CN114588255A (zh) 基于mRNA的肿瘤疫苗及其制备和联合抗癌方法
CN115996733A (zh) 用于免疫疗法的基因工程化γδT细胞
WO2025130934A1 (zh) 表达膜结合型il-15融合蛋白的工程化til及其应用
US20240400989A1 (en) Method for promoting proliferation of immune cells
WO2022260968A1 (en) Compositions and methods for activating natural killer cells
JP2025508076A (ja) Ｔ細胞の利用能を向上させるための抗クローディン－１抗体の使用
JP2024536188A (ja) 抗ｔｎｍｕｃ１ ｇｏｌｄ ｃａｒ ｔ細胞用の組成物および方法
WO2022221669A1 (en) Methods and compositions for treating disease using targeted foxp3+cd4+ t cells and cellular suicide agents
CN118401562A (zh) 抗tnmuc1 gold car t细胞的组合物和方法
WO2021257943A1 (en) Methods of determining responsiveness to cancer immunotherapy
US11364267B1 (en) Bi-specific targeting human NKG2DL and CLDN18A2 chimeric antigen receptor cells, preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Room 303, building 1, 1227 zhangheng Road, Pudong New Area, Shanghai 201203

Applicant after: Yuanqi Biotechnology (Shanghai) Co.,Ltd.

Address before: Room 303, building 1, 1227 zhangheng Road, Pudong New Area, Shanghai 201203

Applicant before: SHANGHAI ORIGINCELL MEDICAL TECHNOLOGY Co.,Ltd.

CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Ling Youguo

Inventor after: Guo Hao

Inventor after: He Xiaowen

Inventor after: Ma Haili

Inventor after: Li Huijiao

Inventor after: Wang Huajing

Inventor after: Ying Bi

Inventor after: Yang Huanfeng

Inventor before: Ling Youguo

Inventor before: Guo Hao

Inventor before: Ma Haili

Inventor before: Li Huijiao

Inventor before: Wang Huajing

Inventor before: Ying Bi

Inventor before: Yang Huanfeng

Inventor before: He Xiaowen

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20390830

TG01 Patent term adjustment